In contemporary oncology, the conduct and evaluation of clinical trials has become a precise ritual, with exact and rigid guidelines. Any attempts to bypass or short-cut the established system is considered unlawful or at least unethical; official recognition and acceptance of a drug or procedure into conventional use depends on adherence of a set of strict rules. This is expected to ensure the safety and efficacy of novel therapeutic modalities ? but does it?
Go to Previous Page